Physicians may soon have another drug Pretomanid in their armamentarium to treat highly drug-resistant tuberculosis (TB) describe as XDR or MDR TB patients. The US Food and Drug Administration (FDA) has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of adult patients with extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) pulmonary TB. It is to be taken orally over six months.
Adverse effects: Peripheral neuropathy, acne, anemia, nausea, vomiting, headache, increased liver enzymes (transaminases and gamma-glutamyltransferase), dyspepsia, rash, hyperamylasemia, visual impairment, hypoglycemia and diarrhea. Contraindication: Hypersensitivity to bedaquiline or linezolid In a study of 109 patients with XDR TB, treatment intolerant or non-responsive MDR pulmonary TB, a success rate of 89% was…
